AbbVie Seeks FDA OK for ABBV-951 in Advanced Parkinson's Disease

By Colin Kellaher

AbbVie Inc. on Friday said it has filed for U.S. Food and Drug Administration approval of ABBV-951 for the treatment of motor fluctuations in patients with advanced Parkinson's disease.

The North Chicago, Ill., biopharmaceutical company said ABBV-951, if approved, would be the first drug to offer continuous subcutaneous delivery of carbidopa/levodopa prodrugs, a commonly used treatment for the neurodegenerative movement disorder.

AbbVie said its application is backed by a Phase 3 study that showed patients had significant increases in hours of "On" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa.

AbbVie said it plans to pursue regulatory submissions for ABBV-951 across international markets throughout the year.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 20, 2022 08:47 ET (12:47 GMT)

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024